This drug is for hormone positive breast cancer and appears to work well at extending the life of a patient. Leronlimab is intended for TNBC, which is breast cancer that is hormone (estrogen and progesterone) negative and HER2 negative. So leronlimab and this drug aren’t necessarily competitors, but I’m glad to see that newer drugs are helping the other form of breast cancers.